Equibles does not estimate personal net worth.
Get an email with a short summary when Lakefront Biotherapeutics NV publishes a filing, an earnings call transcript or a press release.
Get LKFT alertsHenry Gosebruch is recorded as CEO at Lakefront Biotherapeutics NV (LKFT). Earlier roles on record: CEO and Board Member at Neumora Therapeutics, Inc. (NMRA) until February 14, 2025. Neumora Therapeutics, Inc. reported in an 8-K filed February 13, 2025 that Henry Gosebruch resigned as President, Chief Executive Officer, effective February 14, 2025. Neumora Therapeutics, Inc. reported in an 8-K filed February 13, 2025 that Henry Gosebruch resigned as member of the Board, effective February 14, 2025. The proxy statement of Neumora Therapeutics, Inc. reports total compensation of $1,319,273 for Henry Gosebruch in fiscal 2025, including a base salary of $94,231. Disclosed compensation is on record for 3 fiscal years. Henry Gosebruch has spoken on 3 earnings calls and 1 other investor event across 2 companies, most recently for Lakefront Biotherapeutics NV on September 15, 2026. Those appearances were for Lakefront Biotherapeutics NV (LKFT) and Neumora Therapeutics, Inc. (NMRA). Lakefront Biotherapeutics NV is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Henry Gosebruch spoke on are classified in the Healthcare sector.
“Henry Gosebruch will depart the Company and no longer serve as President, Chief Executive Officer or a member of the Board.”
“Henry Gosebruch will depart the Company and no longer serve as President, Chief Executive Officer or a member of the Board.”
“Well, we're delighted to be here, and thanks for hosting us. So we're a clinical stage biopharmaceutical company now with a very exciting portfolio of T-cell engagers with a lead program that is going to start registration studies next year. in four programs in total, and it was quite a journey to get here.”
“It is truly an exciting time to be here. This call marks my one-year anniversary as CEO, and I couldn't be more proud of what we've accomplished together in the first year of our journey.”
“It has been a very active time here at Galapagos as we have worked tirelessly toward advancing the transformation of our company. This transformation has been ongoing for several years, and I firmly believe we have a bright future ahead of us.”
“Good morning, everyone, and thank you for joining us for our first-ever quarterly conference call. Brain diseases collectively represent one of the greatest medical challenges of our generation, affecting upwards of 1.5 billion people globally.”
2023-01-01–2025-02-14
Start not stated–2025-02-14
Biotechnology · Healthcare
CEO
Biotechnology · Healthcare
CEO, Board Member
2023-01-01–2025-02-14
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Neumora Therapeutics, Inc. (NMRA) | Former President and Chief Executive Officer | $94,231 | $1,319,273 |
| 2024 | Neumora Therapeutics, Inc. (NMRA) | President and Chief Executive Officer | $700,000 | $4,785,930 |
| 2023 | Neumora Therapeutics, Inc. (NMRA) | President and Chief Executive Officer | $337,500 | $21,999,269 |
